Exelixis
EXEL
#1636
Rank
A$16.27 B
Marketcap
$58.14
Share price
-0.15%
Change (1 day)
67.02%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) - Total assets

Total assets on the balance sheet as of December 2024 : A$4.66 Billion

According to Exelixis's latest financial reports the company's total assets are A$4.66 Billion. A companyโ€™s total assets is the sum of all current and non-current assets, such as inventories, cash and cash equivalents, properties and equipment.

Exelixis - Total assets on balance sheet (from 2001 to 2024)

Total assets by year

Year Total assets Change
2024-12-31A$4.73 B9.73%
2023-12-31A$4.31 B-4.32%
2022-12-31A$4.51 B25.07%
2021-12-31A$3.60 B29.83%
2020-12-31A$2.77 B3.21%
2019-12-31A$2.69 B33.4%
2018-12-31A$2.01 B140.53%
2017-12-31A$0.83 B1.56%
2016-12-31A$0.82 B81.16%
2015-12-31A$0.45 B15.49%
2014-12-31A$0.39 B-29.99%
2013-12-31A$0.56 B-18.69%
2012-12-31A$0.69 B80.92%
2011-12-31A$0.38 B7.98%
2010-12-31A$0.35 B-7.09%
2009-12-31A$0.38 B-32.85%
2008-12-31A$0.56 B20.76%
2007-12-31A$0.47 B-6.03%
2006-12-31A$0.50 B10.31%
2005-12-31A$0.45 B20.78%
2004-12-31A$0.37 B-21.79%
2003-12-31A$0.48 B-20.03%
2002-12-31A$0.60 B-11.38%
2001-12-31A$0.67 B

Total Assets for similar companies or competitors

Company Total assets differencediff. Country
A$118.06 B 2,431.50%๐Ÿ‡ฌ๐Ÿ‡ง UK
A$218.64 B 4,588.15%๐Ÿ‡ซ๐Ÿ‡ท France
A$185.28 B 3,872.81%๐Ÿ‡บ๐Ÿ‡ธ USA
A$146.51 B 3,041.54%๐Ÿ‡บ๐Ÿ‡ธ USA
A$145.30 B 3,015.63%๐Ÿ‡บ๐Ÿ‡ธ USA
A$284.96 B 6,010.00%๐Ÿ‡บ๐Ÿ‡ธ USA
A$337.63 B 7,139.43%๐Ÿ‡บ๐Ÿ‡ธ USA
A$67.2 M-98.56%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.16 B-96.57%๐Ÿ‡บ๐Ÿ‡ธ USA